The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
Allergy Therapeutics awaits twice-delayed phase III data on its birch pollen project, while Caladrius Biosciences seeks validation of its Treg approach to type 1…
US approval of Lexicon and Sanofi’s SGLT inhibitor in type 1 diabetes hangs in the balance after an adcom tie.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Allergan, Biogen, Bristol-Myers Squibb and Lilly follow Pfizer and Merck & Co on price increases, and there could be more to come at JP Morgan.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.